Alpha7 nicotinic acetylcholine receptor activation protects against myocardial reperfusion injury through modulation of autophagy.

Alpha7 nicotinic acetylcholine receptor (α7nAChR) activation alleviates myocardial ischemia/reperfusion (MI/R) injury. However, the underlying mechanisms remain unclear. Here, we investigated the role of autophagy in α7nAChR-mediated cardioprotection and the molecular mechanisms involved. Activating α7nAChR with PNU-282987 at the initiation of reperfusion reduced myocardial infarct size in MI/R rats. PNU-282987 treatment also significantly inhibited MI/R-induced myocardial autophagy dysfunction as evidenced by the reduction of LC3-II/LC3-I ratio, Beclin-1 and p62 abundance. In addition, PNU-282987 treatment reduced hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury in vitro, accompanied with the inhibition of Beclin-1-associated autophagy and the restoration of autophagic flux. Interestingly, inhibiting autophagic flux attenuated α7nAChR-afforded improvement of mitochondrial function as well as inhibition of apoptosis in vitro. Mechanistically, co-administration of PNU-282987 with LY294002 (a PI3K inhibitor), AG490 (a JAK2 inhibitor) or Bcl-2 siRNA, but not compound C (an AMPK inhibitor), reduced Bcl-2 level and prevented the modulation of autophagy afforded by PNU-282987 in H/R cardiomyocytes. Collectively, these findings suggest that α7nAChR activation inhibits Beclin-1-associated autophagy dysfunction via the JAK2/Bcl-2 and PI3K/Bcl-2 cascades, leading to cardioprotection against MI/R injury.